Beta Bionics partners with Senseonics to integrate iLet bionic pancreas with Eversense 365 CGM

By Public Technologies
  • Beta Bionics entered a partnership with Senseonics to integrate iLet Bionic Pancreas with the Eversense 365 continuous glucose monitor.
  • Commercial launch of the integrated iLet-Eversense 365 system is expected in Q4 2026.
  • The companies also committed to integrate Beta Bionics’ mint automated insulin delivery system with Eversense 365 at a later date.
  • Beta Bionics expects iLet to support the widest range of CGM options among automated insulin delivery systems once the integration launches.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220730PRIMZONEFULLFEED9830868) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.